Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesFRA:IX1 +0.71%96 EV-to-OCF is 34.70 as of Aug. 09, 2026, which is 33% below its 10-year median of 51.60. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €564.83 (Modestly Undervalued). Among 213 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 86.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, IDEXX Laboratories's Enterprise Value is €40,888 Mil.
IDEXX Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €1,178 Mil. Therefore, IDEXX Laboratories's EV-to-OCF for today is 34.70.
The historical rank and industry rank for IDEXX Laboratories's EV-to-OCF or its related term are showing as below:
FRA:IX1'
s EV-to-OCF Range Over the Past 10 Years
Min: 32.13 Med: 51.6 Max: 79.14
Current: 34.35
During the past 13 years, the highest EV-to-OCF of IDEXX Laboratories was 79.14. The lowest was 32.13. And the median was 51.60.
FRA:IX1's EV-to-OCF is ranked worse than 86.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.35
vs FRA:IX1: 34.35
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IDEXX Laboratories's PE Ratio (TTM) for today is calculated as:
IDEXX Laboratories's share price for today is €509.40.
IDEXX Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.235.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
IDEXX Laboratories EV-to-OCF Related Terms
IDEXX Laboratories EV-to-OCF Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's EV-to-OCF falls into.
IDEXX Laboratories's current Enterprise Value is €40,888 Mil.
IDEXX Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a EV-to-OCF of 34.70 as of Aug. 09, 2026. This is 33% below median its historical median of 51.60. Over the past decade, IDEXX Laboratories' EV-to-OCF has ranged from 32.13 to 79.14. According to the industry distribution chart, IDEXX Laboratories ranks #184 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 86.4%.
Is IDEXX Laboratories' EV-to-OCF too high?
IDEXX Laboratories' current EV-to-OCF of 34.70 is 33% below median its 10-year median of 51.60. Over the past 10 years, this metric has ranged from a low of 32.13 to a high of 79.14. The Medical Diagnostics & Research industry median EV-to-OCF is 6.35. IDEXX Laboratories' value of 34.70 is 446.5% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #184 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EV-to-OCF compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #184 out of 213 companies for EV-to-OCF. This places IDEXX Laboratories in the lower half of its industry. The industry median EV-to-OCF is 6.35. IDEXX Laboratories' value of 34.70 is 446.5% above this benchmark. Historically, IDEXX Laboratories' own EV-to-OCF has ranged from 32.13 to 79.14 over the past decade. While the company's 10-year median is 51.60 vs. the industry median of 6.35, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.35, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current EV-to-OCF of 34.70 is 446.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EV-to-OCF is 34.70, which is 33% below median its own 10-year median of 51.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €564.83, compared to a current price of €509.40 — trading 9.8% below its estimated fair value. The current EV-to-OCF is 34.70, which is 33% below median its 10-year median of 51.60 and 446.5% above the Medical Diagnostics & Research industry median of 6.35. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EV-to-OCF is 34.70 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €509.40 is trading 9.8% below its estimated GF Value™ of €564.83.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
EV-to-OCF: 34.70 (33% below median its 10-year median of 51.60)
GF Value™: €564.83 vs. price of €509.40 (9.8% below fair value)
Industry Position: 446.5% above the Medical Diagnostics & Research median (#184 of 213)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
